Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200633 | 0.84 | MMP2 (0.38) | CNR2MEN1KMT2AMAOBALDH1A1 | |
| SCHEMBL6202677 | 0.84 | TBXA2R (0.40) | CNR2MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7837755 | 0.83 | CNR2 (0.35) | CNR2APPMEN1KMT2AMAOB | |
| SCHEMBL7846237 | 0.83 | APP (0.34) | CNR2APPMEN1KMT2AMAOB | |
| SCHEMBL6201097 | 0.80 | CNR1 (0.38) | CNR2ALDH1A1CNR1 | |
| SCHEMBL6202014 | 0.80 | SLC10A2 (0.33) | CNR2APPMEN1KMT2AMAOB | |
| SCHEMBL16385373 | 0.78 | MAOB (0.33) | APPMAOBMAOACALM1SLC10A2 | |
| SCHEMBL7846110 | 0.77 | CNR2 (0.37) | CNR2APPMEN1KMT2ACALM1 | |
| SCHEMBL7837233 | 0.76 | MEN1 (0.35) | CNR2APPMEN1KMT2AMAOB | |
| SCHEMBL6202055 | 0.74 | CNR1 (0.38) | CNR2ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-11376251-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220023296-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11229661-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200207797-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | LUMENA PHARMACEUTICALS LLC (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190169217-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | LUMENA PHARMACEUTICALS LLC (US) | 2019-06-06 | — | — | US | disclosed |
| US-20170368085-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20030232834-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | KELLER BRADLEY T (US) | 2003-12-18 | — | — | US | disclosed |
| WO-2003022804-A9 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | G.D. SEARLE, LLC (US) | 2003-10-23 | — | — | US | disclosed |
| US-6586434-B2 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2003-07-01 | — | — | US | disclosed |
| WO-2003040127-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. SEARLE LLC (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003022804-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. SEARLE LLC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1286984-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | Pharmacia Corporation (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020061888-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | G.D. SEARLE LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE LLC | 2002-03-14 | — | — | US | disclosed |
| WO-2001068637-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169217-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | CNR2 3681/4885APP 3747/4885MEN1 3173/4885 |
| US-20220023296-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | CNR2 4747/4885APP 2588/4885MEN1 2972/4885 |
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | CNR2 3681/4885APP 3747/4885MEN1 3173/4885 |
| US-20170368085-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | CNR2 4747/4885APP 2588/4885MEN1 2972/4885 |
| US-11376251-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SLC10A1, SLC10A2, ABCB11 | CNR2 4747/4885APP 2588/4885MEN1 2972/4885 |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | TPMT, MPST, SULT1A1 | CNR2 4152/4885APP 1108/4885MEN1 3859/4885 |
| US-20030232834-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | TOP2A, TOP2B, TYMP | CNR2 1504/4885APP 4422/4885MEN1 2266/4885 |
| US-20200207797-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | CNR2 3681/4885APP 3747/4885MEN1 3173/4885 |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | CNR2 2107/4885APP 1615/4885MEN1 1887/4885 |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | SLC10A2, SLC10A1, ABCB11 | CNR2 3998/4885APP 4490/4885MEN1 3677/4885 |
| US-11229661-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SLC10A1, SLC10A2, ABCB11 | CNR2 4747/4885APP 2588/4885MEN1 2972/4885 |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | CNR2 4747/4885APP 2588/4885MEN1 2972/4885 |
| US-20020061888-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | SLC10A1, HMGCR, SLC10A2 | CNR2 3380/4885APP 3945/4885MEN1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.